Flash Finance

Granules India LimitedGRANULESCorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹825.35
MCap ₹20,452 Cr · P/E 30.9
Granules India Limited — Stock analysis & AI research Granules India Limited — Multibagger AI analysis Granules India Limited — Seasonality — best & worst months Granules India Limited — Technical indicators & charts Granules India Limited — Technical setup — score, trend, support & resistance Granules India Limited — Triple Top pattern forming Granules India Limited — Live exchange announcements
📋 Stocks With Strong Quarterly Results📋 Small Cap Stocks List 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹1,477 Cr
Sales · Jun 2026
+22.0% YoY
₹339 Cr
Operating Profit · Jun 2026
+37.2% YoY
22.9%
OPM % · Jun 2026
+12.3% YoY
₹180 Cr
Net Profit · Jun 2026
+59.3% YoY
₹7.26
EPS · Jun 2026
+56.5% YoY

📝 Granules India Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Granules India Limited reported revenue of ₹1,477 crore for the quarter ended June 2026 (Q1 FY27), up 22.0% from ₹1,210 crore in the same quarter last year, and up 0.4% sequentially over the March 2026 quarter.

Net profit rose 59.3% year-on-year to ₹180 crore, from ₹113 crore. Earnings per share (EPS) came in at ₹7.26.

Operating profit stood at ₹339 crore — an operating margin (OPM) of 22.9%, compared with 20.4% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Granules India Limited posted revenue of ₹5,366 crore, a growth of 19.7% over FY25, with a net profit of ₹596 crore (up 18.8% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹5,633 crore with a net profit of ₹663 crore.

Valuation snapshot

At the current price of ₹825.35, GRANULES has a market capitalisation of ₹20,452 crore and a trailing P/E of about 30.9.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 22nd-largest of the 31 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 37.39%, foreign institutional investors (FIIs) 20.29%, domestic institutional investors (DIIs) 15.40%, public shareholders 26.93% of Granules India Limited.

Promoter holding slipped from 38.02% to 37.39% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹20,452 Cr
Current Price ?
₹825.4
P/E ?
30.87below ind
Industry P/E ?
35.00
P/B ?
4.02
P/S ?
3.63
P/FCF ?
85.57
Enterprise Value ?
₹21,964 Cr
EV/EBITDA ?
17.20
PEG ?
6.17
Earnings Yield ?
4.4%
Dividend Yield ?
0.21%
Profitability & Returns
Sales (TTM) ?
₹5,633 Cr
OPM ?
22.7%
Profit after tax (TTM) ?
₹663 Cr
EPS (TTM) ?
₹26.74
ROCE ?
15.0%
ROE ?
13.0%
ROA ?
8.6%
Growth
Sales — latest qtr ?
₹1,477 Cr
PAT — latest qtr ?
₹180 Cr
YoY qtr sales growth ?
22.0%
YoY qtr profit growth ?
59.3%
Sales growth (3y) ?
6%
Sales growth (5y) ?
11%
Profit growth (3y) ?
5%
Profit growth (5y) ?
2%
Financial Health
Debt ?
₹1,512 Cr
Debt to Equity ?
0.30
Interest Coverage ?
7.7
Current Ratio ?
N/A
Ownership
Promoter holding ?
37.39%
Change in promoter holding ?
-1.43%
Pledged percentage ?
N/A
Market
Return 3 months ?
-6.3%
Return 6 months ?
25.9%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 1,1461,1969861,1891,1561,1761,1809671,1381,1971,2101,2971,3881,4711,477 +22.0% +0.4%
Operating Profit 231228137213250256259203230252247278308352339 +37.2% -3.7%
Other Income 1302122362-10-1-4252 +122.7% -90.9%
Interest 171922262929272627242429293321 -12.0% -36.0%
Depreciation 484949535253535357646972748280 +15.4% -2.9%
Profit Before Tax 16716465136170176181128153198145176202262240 +65.8% -8.2%
Net Profit 1241204810212613013597118152113131150202180 +59.3% -10.9%
EPS 5.114.941.984.225.185.355.564.014.856.274.645.386.198.137.26 +56.5% -10.7%
OPM % 20.2% 19.1% 13.9% 17.9% 21.7% 21.7% 22.0% 21.0% 20.2% 21.1% 20.4% 21.5% 22.2% 23.9% 22.9% +12.3% -4.2%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹4,482 Cr ₹5,366 Cr ₹5,633 Cr +19.7%
Operating Profit ₹945 Cr ₹1,185 Cr ₹1,277 Cr +25.4%
OPM % 21.08% 22.09% 22.67% +4.8%
NPM % 11.18% 11.10% 11.76% -0.7%
Other Income ₹13 Cr ₹10 Cr ₹22 Cr -22.2%
Depreciation ₹226 Cr ₹297 Cr ₹308 Cr +31.4%
Interest ₹104 Cr ₹115 Cr ₹112 Cr +11.2%
EBIT ₹719 Cr ₹888 Cr ₹969 Cr +23.5%
PBT ₹660 Cr ₹785 Cr ₹880 Cr +19.0%
Tax ₹127 Cr ₹45 Cr ₹106 Cr -64.5%
Net Profit ₹501 Cr ₹596 Cr ₹663 Cr +18.8%
EPS ₹20.69 ₹24.34 ₹26.96 +17.6%
Material Cost ₹1,362 Cr ₹498 Cr ₹994 Cr -63.5%
Employee Cost ₹500 Cr ₹219 Cr ₹474 Cr -56.2%
Extraordinary Items ₹31 Cr — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 24242425 +4.2%
Reserves 2,8113,2013,6915,060 +37.1%
Borrowings 1,1361,3151,4551,512 +3.9%
Other Liabilities 9329571,0511,123 +6.9%
Total Liabilities 4,9035,4986,2217,720 +24.1%
Fixed Assets 1,9112,0962,4263,253 +34.1%
CWIP 239272440406 -7.7%
Investments 2122221 -95.5%
Other Assets 2,7323,1093,3334,059 +21.8%
Total Assets 4,9035,4986,2217,720 +24.1%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 739439867793 -8.5%
Cash from Investing Activity -192-358-689-773 -12.2%
Cash from Financing Activity -4408-93379 +507.5%
Net Cash Flow 1079085399 +369.4%
Free Cash Flow 32861297239 -19.5%
CFO/OP 100%73%107%87% -18.7%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 77807762 -19.5%
Inventory Days 182235284326 +14.8%
Days Payable 124135154131 -14.9%
Cash Conversion Cycle 135179207256 +23.7%
Working Capital Days 36354249 +16.7%
ROCE % 19%15%15%15% +0.0%

👥 Shareholding (latest 6 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026 % Chg
Promoters 38.82%38.81%38.81%38.02%38.02%37.39% -1.7%
FIIs 13.24%14.09%13.55%15.31%17.50%20.29% +15.9%
DIIs 23.52%17.91%17.47%17.01%16.11%15.40% -4.4%
Public 24.41%29.17%30.15%29.67%28.38%26.93% -5.1%
No. of Shareholders 1,69,7001,65,5421,63,1841,60,2861,69,4221,82,080 +7.5%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 ASTRAZEN AstraZeneca Pharma ₹6,755.00 16,888 99.6 2,432 170 9.4% 7.0% 32.7% 62.1% 29.7% -32.1%
❓ Frequently asked questions
What was Granules India Limited's revenue in Q1 FY27?
Granules India Limited reported revenue of ₹1,477 crore for the quarter ended June 2026 (Q1 FY27), up 22.0% from ₹1,210 crore in the same quarter last year, and up 0.4% sequentially over the March 2026 quarter.
What was Granules India Limited's net profit in Q1 FY27?
Net profit rose 59.3% year-on-year to ₹180 crore, from ₹113 crore. Earnings per share (EPS) came in at ₹7.26.
What is GRANULES's market capitalisation and P/E ratio?
At the current price of ₹825.35, GRANULES has a market capitalisation of ₹20,452 crore and a trailing P/E of about 30.9.
Who owns Granules India Limited? (shareholding pattern)
As of Sep 2026, promoters held 37.39%, foreign institutional investors (FIIs) 20.29%, domestic institutional investors (DIIs) 15.40%, public shareholders 26.93% of Granules India Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI